犬异位性皮肤炎治疗药物市场，依药物类别、依给药途径、按剂型、依配销通路、地理位置

预计2024年犬异位性皮肤炎治疗药物市场价值为14.944亿美元，预计到2031年将达到29.366亿美元，2024年至2031年的年复合成长率（CAGR）为10.1%。

图 1. 份额 (%)，按地区划分，2024 年

犬异位性皮肤炎是在家犬中观察到的慢性皮肤病。其特征是皮肤发炎和感染。在过去的几十年里，宠物狗中异位性皮肤炎的盛行率一直在增加。确切原因尚不清楚，但据信涉及遗传和环境因素，导致免疫系统对通常无害的物质反应过度。患有异位性皮肤炎的狗狗会经历严重的搔痒、发炎和皮肤损伤，导致不适。传统上使用抗组织胺和皮质类固醇来控制症状。然而，它们不能治癒这种疾病，长期使用会引起副作用。因此，需要能够缓解症状和改变疾病的安全有效的治疗药物。多家製药公司正在投资研究和开发标靶生物製剂、免疫调节剂和其他新型治疗方法。

市场动态：

全球犬异位性皮肤炎治疗药物市场受到宠物拥有量增加、研发活动增加、犬异位性皮肤炎盛行率增加以及新产品推出等因素的推动。近年来，市场见证了多种新药的批准和上市，扩大了可用的治疗选择。然而，与新药相关的高治疗成本是一个限制因素。市场参与者有机会在未开发的新兴市场中实现成长，并进一步开发先进疗法。

研究的主要特点：

• 该报告对全球犬异位性皮肤炎治疗药物市场进行了深入分析，并提供了预测期（2024-2031）的市场规模（百万美元）和年复合成长率（CAGR%），以2023年为基础年。
• 它阐明了不同细分市场的潜在收入成长机会，并解释了该市场有吸引力的投资主张矩阵。
• 这项研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采取的竞争策略的重要见解。
• 它根据以下参数介绍了全球犬异位性皮肤炎治疗药物市场的主要参与者——公司亮点、产品组合、主要亮点、财务表现和策略。
• 该报告的见解将使行销人员和公司管理当局能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 全球犬异位性皮肤炎治疗药物市场迎合了该行业的各个利益相关者，包括投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
• 利害关係人可以透过用于分析全球犬异位性皮肤炎治疗药物市场的各种策略矩阵轻鬆做出决策。

目录

第一章：研究目标与假设

• 研究目标
• 假设
• 缩写

第 2 章：市场范围

• 报告说明
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map (COM)

第 3 章：市场动态、法规与趋势分析

• 市场动态
  • 司机
  • 限制
  • 机会
• 影响分析
• 市场走向
• 最近的发展
• 品牌和定价分析
• 监管场景
• 收购和合作场景
• 产品发布/批准
• 资金和投资
• PEST分析
• 波特的分析

第 4 章：全球犬异位性皮肤炎治疗药物市场 - 冠状病毒 (COVID-19) 大流行的影响

• 整体影响
• 政府倡议
• COVID-19 对市场的影响

第 5 章：2019 - 2031 年全球犬异位性皮肤炎治疗药物市场（依药物类别）（百万美元）

• 概述
• Janus 激酶抑制剂
• 抗组织胺药
• 单株抗体
• 抗生素
• 过敏免疫治疗/脱敏治疗
• 其他的

第 6 章：全球犬异位性皮肤炎治疗药物市场，依给药途径，2019 - 2031 年（百万美元）

• 概述
• 可注射
• 口服
• 专题

第 7 章：全球犬异位性皮肤炎治疗药物市场，按剂型，2019 - 2031 年（百万美元）

• 概述
• 平板电脑
• 乳霜
• 喷
• 其他的

第 8 章：全球犬异位性皮肤炎治疗药物市场，按配销通路，2019 - 2031 年（百万美元）

• 概述
• 在线的
• 离线

第 9 章：2019 - 2031 年全球犬异位性皮肤炎治疗药物市场（按地区）（百万美元）

• 介绍
• 北美洲
• 我们
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 拉丁美洲其他地区
• 欧洲
• 英国
• 德国
• 义大利
• 法国
• 西班牙
• 俄罗斯
• 欧洲其他地区
• 亚太地区
• 中国
• 印度
• 日本
• 东协
• 澳洲
• 韩国
• 亚太地区其他地区
• 中东
• 海湾合作委员会
• 以色列
• 中东其他地区
• 非洲
• 北非
• 中非
• 南非

第 10 章：竞争格局

• 公司简介
  • Bioiberica SAU
  • Dechra Pharmaceuticals PLC
  • Elanco
  • NIPPON ZENYAKU KOGYO CO., LTD
  • Vimian
  • TORAY INDUSTRIES, INC.
  • Zoetis
  • Virbac
  • Ceva
  • Bimeda, Inc.
  • Vivaldis
  • VetriMax Veterinary Products
  • Vetoquinol
  • Royal Canin North America

第 11 章：分析师观点

• 命运之轮
• 分析师观点
• 连贯的机会图

第 12 章：参考文献与研究方法

• 参考
• 研究方法论

The canine atopic dermatitis treatment drugs market is estimated to be valued at USD 1,494.4 Mn in 2024 and is expected to reach USD 2,936.6 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 10.1% from 2024 to 2031.

Figure 1. Share (%), By Region, 2024

Canine atopic dermatitis is a chronic skin condition observed in domestic dogs. It is characterized by inflammation and infections of the skin. The prevalence of atopic dermatitis has been increasing among pet dogs over the past few decades. The exact causes are unknown, but it is believed to involve genetic and environmental factors that cause the immune system to overreact to substances that are normally harmless. Dogs with atopic dermatitis experience severe itching, inflammation, and skin lesions that lead to discomfort. Antihistamines and corticosteroids have traditionally been used to manage the symptoms. However, they do not cure the condition and long-term use can cause side effects. Therefore, there is a need for safe and effective treatment drugs that can relieve symptoms and modify the disease. Several pharmaceutical companies are investing in research and developing targeted biologics, immunomodulators, and other novel treatment approaches.

Market Dynamics:

The global canine atopic dermatitis treatment drugs market is driven by factors such as rising pet ownership, rising research and development activities, and increasing prevalence of canine atopic dermatitis, and new product launches. The market has witnessed the approval and launch of several new drugs in recent years which has expanded the treatment options available. However, high treatment costs associated with novel drugs is a restraint. The market players have opportunities for growth in untapped emerging markets and further development of advanced therapeutics.

Key Features of the Study:

• This report provides an in-depth analysis of the global canine atopic dermatitis treatment drugs market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global canine atopic dermatitis treatment drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Bioiberica S.A.U, Dechra Pharmaceuticals PLC, Elanco, NIPPON ZENYAKU KOGYO CO., LTD, Vimian, TORAY INDUSTRIES, INC., Zoetis, Virbac, Ceva, Bimeda, Inc., Vivaldis, VetriMax Veterinary Products, Vetoquinol, and Royal Canin North America.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global canine atopic dermatitis treatment drugs market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global canine atopic dermatitis treatment drugs market.

Detailed Segmentation-

• Drug Class:
  • Janus Kinase Inhibitors
  • Antihistamines
  • Monoclonal Antibodies
  • Antibiotics
  • Allergic Immunotherapy/Desensitization Therapy
  • Others
• Route of Administration:
  • Injectable
  • Oral
  • Topical
• Dosage Form:
  • Tablets
  • Creams
  • Spray
  • Others
• Distribution Channel:
  • Online
  • Offline
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Bioiberica S.A.U
  • Dechra Pharmaceuticals PLC
  • Elanco
  • NIPPON ZENYAKU KOGYO CO., LTD
  • Vimian
  • TORAY INDUSTRIES, INC.
  • Zoetis
  • Virbac
  • Ceva
  • Bimeda, Inc.
  • Vivaldis
  • VetriMax Veterinary Products
  • Vetoquinol
  • Royal Canin North America

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Dosage Form
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Brand and Pricing Analysis
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Canine Atopic Dermatitis Treatment Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 impact on the market

5. Global Canine Atopic Dermatitis Treatment Drugs Market, By Drug Class, 2019 - 2031, (USD Mn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Janus Kinase Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Antihistamines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Monoclonal Antibodies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Antibiotics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Allergic Immunotherapy/Desensitization Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Global Canine Atopic Dermatitis Treatment Drugs Market, By Route of Administration, 2019 - 2031, (USD Mn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Injectable
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Topical
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Global Canine Atopic Dermatitis Treatment Drugs Market, By Dosage Form, 2019 - 2031, (USD Mn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Tablets
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Creams
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Spray
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

8. Global Canine Atopic Dermatitis Treatment Drugs Market, By Distribution Channel, 2019 - 2031, (USD Mn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Online
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Offline
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

9. Global Canine Atopic Dermatitis Treatment Drugs Market, By Region, 2019 - 2031, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Regions, 2019-2031
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Mn)
• North Africa
• Central Africa
• South Africa

10. Competitive Landscape

• Company Profiles
  • Bioiberica S.A.U
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Market Strategies
  • Dechra Pharmaceuticals PLC
  • Elanco
  • NIPPON ZENYAKU KOGYO CO., LTD
  • Vimian
  • TORAY INDUSTRIES, INC.
  • Zoetis
  • Virbac
  • Ceva
  • Bimeda, Inc.
  • Vivaldis
  • VetriMax Veterinary Products
  • Vetoquinol
  • Royal Canin North America

11. Analyst View

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact